Skip to main content

Advertisement

SpringerLink
Log in

Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities

  • Original Article
  • Published:
Molecular Diversity Aims and scope Submit manuscript

Abstract

A series of ciprofloxacin/thiazolidine-2,4-dione hybrids 3a-m were prepared and identified by IR, 1HNMR, 13CNMR and elemental analysis. The antibacterial activity results of the designed hybrids revealed a shift of spectrum toward Gram-positive bacteria. They exhibited excellent activity against S. aureus ATCC 6538, with the most potent compounds being 3a, 3e, 3g, 3i, 3k, 3l and 3m possessing MICs of 0.02, 2.03, 0.64, 0.35, 1.04, 0.22 and 0.36 µM, respectively, compared to their parent compound ciprofloxacin (MIC: 5.49 µM). They also showed interesting activity against MRSA AUMC 261 with 3a, 3e and 3l showing MIC values of 5 nM. Reduced activity was observed against Gram-negative bacteria with compound 3l exhibiting a slightly higher activity against K. pneumoniae ATCC10031 with a MIC value of 0. 08 µM. Mechanistically, the incorporation of thiazolidine-2,4-dione ring into ciprofloxacin retained its ability to inhibit DNA synthesis via inhibiting both topoisomerase IV and DNA gyrase of S. aureus. Compounds 3a, 3l and 3m were more potent than ciprofloxacin for topoisomerase IV (IC50 = 0.3–1.9 μM) and gyrase (IC50 = 0.22–0.31 µM) inhibition, which coincide with their antibacterial activity against S. aureus ATCC 6538. Docking against DNA gyrase active site confirmed the ability of the tested compounds to form stable complexes with the enzyme; like that of ciprofloxacin, 3a, 3i, 3k, 3m and 3l reconsidered promising broad-spectrum antibacterial agents targeting topoisomerase IV and gyrase enzymes and have good activity against MRSA.

Graphic Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Scheme 1
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Hopeer DC (2001) Emerging mechanisms of fluoroquinolones resistance. Emerg Infect Dis 7 (2): 337–341. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631735

  2. Bisacchi GS (2015) Origins of the quinolone class of antibacterials: an expanded “discovery story” miniperspective. J Med Chem 58: 4874–4882. https://pubs.acs.org/doi/abs/https://doi.org/10.1021/jm501881c

  3. Redgrave LS, Sutton SB, Webber MA, Piddock LJV (2014) Fluoroquinolone resistance: mechanisms, impact on bacteria and role in evolutionary success. Trends Microbio 22: 438–445. https://www.sciencedirect.com/science/article/abs/pii/ S0966842X14000894

  4. Anderson VE, sheriff NO (2001) Type II topoisomerase as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des 7: 337–35. https://www.ingentaconnect.com/content/ben/cpd/2001/00000007/00000005/art00003

  5. Champoux JJ (2001) DNA topoisomerases: structure, function and mechanism. Ann Rev Biochem 70: 369–413. https://www.annualreviews.org/doi/abs/ 10.1146/

  6. Drlica K, Malik M, Kerns R J, Zhao X (2008) Quinolones mediated bacterial death. Antimicrob Agents Chemother 52: 385–392. https://aac.asm.org/content/52/2/385

  7. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E (2004) Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 48: 1281–1288. https://pubmed.ncbi.nlm.nih.gov/15047530

  8. Finch RG (1995) The role of new quinolones in the treatment of respiratory tract infections. Drugs 49(2): 144–151. https://link.springer.com/article/https://doi.org/10.2165/00003495-199500492-00024

  9. Gillespie SH, Crook AM, Mchugh TD, Mendel CM, Meredith SK, Murray SR, Nunn AJ (2014) Four- month moxifloxacin-based regimens for drug- sensitive tuberculosis. New Eng J Med 371: 1577–1587. https://www.nejm.Org /doi/full/https://doi.org/10.1056/NEJMoa1407426

  10. Aziz HA, Mustafa GAI, Abbas SH, Hauk G, Krishna VS, Sriram D, Berger JM, Abuo-Rahma GEDA (2019) New fluoroquinolone/nitric oxide donor hybrids: design, synthesis and antitubercular activity. Med Chem Res 28: 1272–1283. https://link.springer.com/article/https://doi.org/10.1007/s00044-019-02372-y

  11. Khan KM, Siddiqui R, Ambreen N, Sultana N, Tauseef S, Ahmad A, Parveen S (2012) Synthesis, antibacterial and antifungal evaluation of norfloxacin derivatives. J Pharm Res 5: 666. https://www.researchgate.net/profile/Saima-Tauseef/publication/225082056

  12. Dey R, Bishayi B (2020) Dexamethasone along with ciprofloxacin modulates S. aureus induced microglial inflammation via glucocorticoid (GC)-GC receptor-mediated pathway. Micro Pathog 145: 104227. https://www.sciencedirect.com/science /article/ abs/pii/S0882401020305143

  13. Pudlo M, Luzet V, Ismaili L, Tomassoli I, Iutzeler A, Refouvelet B (2014) Quinolone–benzyl piperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer Disease. Bioorg Med Chem 22(8): 2496–2507. https://www.sciencedirect.com/science/article/abs/pii/S0968089614001527

  14. Li J, Li S, Bai C, Liu H, Gramatica P (2013) Structural requirements of 3-carboxyl-4 (1H)-quinolones as potential antimalarials from 2D and 3D QSAR analysis. J Mol Graph Model 44: 266. https://pubmed.ncbi.nlm.nih.gov/23911994/

  15. Daneshtalab M, Ahmed A (2011) Non classical biological activities of quinolones derivatives. J Pharm Pharm Sci 15(1): 5272. https://journals.libraryualberta.ca/jpps/index.php/jpps/article/view/12211

  16. Mohamed HHH, Abbas SH, Hayallah AM, Abuo-Rahma GEDA, Mostafa YA (2020) Novel urea linked ciprofloxacin-chalcone hybrids having antiproliferative, topoisomerases I/II inhibitory activities and caspases-mediated apoptosis. Bioorg Chem 106: 104422. https://www.sciencedirect.com/science/article/abs/pii/ S0045206 82031720X

  17. Hu YO, Zhang S, Xu Z, Lv ZS, Liu ML, Feng LS (2017) 4-Quinolone hybrids and their antibacterial activities. Eur J Med Chem 141: 335. https://www.sciencedirect .com/science/article/abs/pii/S022352341730765

  18. Fedorowicz J, Sączewski J (2018) Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules Monatsheft efür Chemie-Chemical Monthly 149(7): 1199–1245. https://link.springer.com/article/https://doi.org/10.1007/s00706-018-2215-x

  19. Abuo-Rahma GEDA, Sarhan HA, Gad GA(2009) Design, synthesis, antibacterial activity and physiochemical parameters of novel N-4-piperazinyl derivatives of norfloxacin. Bioorg Med Chem 17: 3879–3886. https://www.sciencedirect.com/science/article/abs/pii/S0968089609003873

  20. Mohammed HHH, Abdelhafez ESMN, Abbas SH, Moustafa GAI, Hauk G, Berger JM, Mitarai S, Arai M, Abd-El baky RM, Abuo-Rahma GEDA (2019) Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity. Bio Org Chem 88: 102952. https://www.sciencedirect.com/science/article/abs/pii/S0045206818308988

  21. Aziz HA, Moustafa GAI, Abuo-Rahma GEDA, Rabea SM, Hauk G, Krishna VS, Sriram D, Berger JM, Abbas SH (2020) Synthesis and antimicrobial evaluation of new nitric oxide-donating fluoroquinolone/oxime hybrids. Arch Der Pharm 2000180. https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1002/ardp.202000180

  22. Sriram D, Aubry A, Yogeeswari P, Fisher LM (2006) Gatifloxacin derivatives: synthesis, antimycobacterial activities and inhibition of Mycobacterium tuberculosis DNA gyrase. Biorg Med Chem lett 16: 2982–2885. https://www.sciencedirect. com/science/article/abs/pii/S0960894X06002502

  23. Zhang L, Kumar KV, Geng RX, Zhou CH (2015) Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu2+ mediated DNA-targeting antibacterial agents. Bioorg Med Chem Lett 25. 17: 3699–3705. https://www.sciencedirect.com/science/article/abs/pii/S0960894X15006344

  24. Domalaon R, Idowu T, Zhanel GG, Schweizer F (2018) Antibiotic hybrids: the next generation of agents and adjuvants against Gram-negative pathogens. Clin Microbio Rev 31(2).‏ https://cmr.asm.org/content/31/2/e00077-17

  25. Asati V, Mahapatra DK, Bharti SK (2014) Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: potential anticancer agents. Eur J Med Chem 87: 814833.https://www.sciencedirect.com/science/article/abs/pii/S0223523414009520

  26. Pokrovskaya V, Baasov T (2010) Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin Drug Discov 5(9): 883–902. https://www.tandfonline.com/doi/abs/https://doi.org/10.1517/17460441.2010.508069

  27. Yadav V, Talwar P (2019) Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed Pharmacother 111: 934–946. https://www.sciencedirect.com/science/article/pii/S0753332218370689

  28. Pokrovskaya V, Belakhov V, Hainrichson M, Yaron S, Baasov T (2009) Design, synthesis, and evaluation of novel fluoroquinolone−aminoglycoside hybrid antibiotics. J Med chem 52 (8): 2243–2254.‏ https://pubs.acs.org/doi/abs/https://doi.org/10.1021/jm900028n.

  29. Menteşe M, Beriş FS, Demirbaş N (2017) Synthesis of some new ciprofloxacin hybrids as potential antimicrobial agents. J Heterocy Chem 54 (6): 2996–3007.‏ https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1002/jhet.2907

  30. Xu Z, Zhao SJ. Deng JL, Wang Q, Lv ZS (2019) Ciprofloxacin–Isatin hybrids and their antimycobacterial activities. J Heterocy Chem 56(1): 319–324. ‏https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1002/jhet.3382

  31. Xu Z, Zhao SJ, Lv ZS, Gao F, Wang Y, Zhang F, Deng JL (2019) Fluoroquinolone-isatin hybrids and their biological activities. Europ J Med Chem 162: 396–406.‏ https://www.sciencedirect.com/science/article/abs/pii/S0223523418309917

  32. Mohammed HH, Abbas SH, Abdelhafez ESM, Berger JM, Mitarai S, Arai M, Abuo-Rahma GEDA (2019) Synthesis, molecular docking, antimicrobial evaluation, and DNA cleavage assay of new thiadiazole/oxadiazole ciprofloxacin derivatives. Monatsh Chem Chem Mon 150 (10): 1809–1824. https://link.springer.com/article/https://doi.org/10.1007/s00706-019-02478-4‏

  33. Gordeev MF, Hackbarth C, Barbachyn MR, Banitt LS, Gage JR, Luehr GW, Patel DV (2003) Novel oxazolidinone–quinolone hybrid antimicrobials. Biorg Med Chem lett 13(23): 4213–4216.‏ https://www.sciencedirect.com/science/article/abs/pii/ S0960894X03008813

  34. Momose Y, Maekawa T, Yamano T, Kawada M, Audaka H, Ikeda H, Sohda T (2002) 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives, as insulin sensitizers with antidiabetic activities. J Med Chem 45 (7): 1518–1534. https://pubs.acs.org/doi/abs/https://doi.org/10.1021/jm010490l

  35. Fois B, Skok Z, Tomašič T, Ilaš J, Zidar N, Zega A, Kikelj D (2020) Dual Escherichia coli DNA gyrase A and B inhibitors with antibacterial activity. Chem Med Chem 15 (3): 265–269. https://pubmed.ncbi.nlm.nih.gov/31721445/

  36. Pattan SR, Alagwadi KR, Bhat AR, Reddy VVK, Pattan JS, Khade AB, Bhatt KG (2008) Synthesis and evaluation of some 5-[1-{4–4-substituted phenyl amino}-meth-(Z)-ylidene]-thiazolidine-2,4-dione for antitubercular activity. Indian Drugs 45: 532–535. https://scholar.google.com/scholar?cluster=10993626715569165669

  37. Nitsche C, Schreier VN, Behnam MAM, Kumar A, Bartenschlager R (2013) Thiazolidinone–peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture C. D. Klein. J Med Chem. 56 (21): 8389–8403. https://pubs.acs.org/doi/abs/https://doi.org/10.1021/jm400828u

  38. Bahare RS, Ganguly S, Choowongkomon K, Seetaha S (2015) Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones. DARU J Pharm Sci 23: 6. https://link.springer.com/article/https://doi.org/10.1186/s40199-014-0086-1

  39. Swathi N, Ramu Y, Subrahmanyam CVS, Satyanarayana K (2012) Synthesis, quantum mechanical calculation and biological evaluation of 5-(4-substituted aryl/hetero aryl methylidene)-1,3-thiazolidine-2,4-diones. Int J Pharm Sci 4: 561–566. https://www.researchgate.net/publication/288233808

  40. Rekha S, Shantharam U, Vineet C, Synthesis and evaluation of novel thiazolidinedione for anti-inflammatory activity. Inter. Reser. J. Pharm 2(9): 81–84. https://www.researchgate.net/publication/285800702

  41. El-Feky SAH (1993) Synthesis and anticonvulsant properties of some quinazolinone thiazolidine and 4-thiazolidinone derivatives. Pharmazie 48: 894–896. https://europepmc.org/article/med/8115435

  42. Alegaon SG, Alagawadi KR (2012) New thiazolidinedione-5-acetic acid amide derivatives: synthesis, characterization and investigation of antimicrobial and cytotoxic properties. Med Chem Res 21: 816–824. https://link.springer.com/article/10.1007/ s00044-011-9598-0

  43. Pinheiro DS, Junior ENS, Consolini G, Aguiar MJ, Silva RRO (2017) Optimized synthesis and characterization of Thiazolidine-2,4-dione for pharmaceutical application. MOJ Biorg Org Chem 1(4): 122–126.‏ https://www.researchgate.net/profile/Danilo-Pinheiro-2/publication/319776178

  44. Khan FAK, Jadhav KS, Patil RH, Shinde DB, Arote RB, Sangshetti JN (2016) Biphenyl tetrazole-thiazolidinediones as novel bacterial peptide deformylase inhibitors: synthesis, biological evaluations and molecular docking study. Biomed Pharmacother 83: 1146–1153. https://www.sciencedirect.com/science/article/abs/pii/ S0753332216308010

  45. Yang DH, Gao HL, Yang BY, Chen ZC (2008) Ionic liquid-accelerated N-arylation of 5-arylidene-2, 4-thiazolidinediones with diaryliodonium salts, J Chem Res 12: 686–687. https://journals.sagepub.com/doi/abs/https://doi.org/10.3184/030823408X382144

  46. Holzgrabe U., Branch SK (1994) 19F and 13C NMR spectral data of fifteen gyrase inhibitors and some metabolites. Magn Resonance chem 32 (3): 192–196.‏ https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1002/mrc.1260320313

  47. Bonev B, Hooper J, Parisot J (2008) Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. J Antimicrob Chemother 61: 1295. https://academic.oup.com/jac/article/61/6/1295/739753

  48. Daneshtalab M, Ahmed A (2011) Non-classical biological activities of quinolones derivatives. J Pharm Pharm Sci 15: 52. https://journals.library. ualberta.ca/jpps/index.php/jpps/article/view/12211

  49. Ezelarab HA, Abbas SH, Hassan HA, Abuo Rahma GEDA (2018) Recent updates of fluoroquinolones as antibacterial agents. Arch Pharm 351(9): 1800141.‏ https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1002/ardp.201800141

  50. Shelke KF (2015) Cellulose sulphuric acid as an efficient catalyst for the synthesis of 5-arylidene-2, 4-thiazolidinedione under microwave irradiation. Org chem 11(4): 129–132. https://www.researchgate.net/publication/303547999

  51. Shyam SK, Sandeep RCH, Sowjanya S, Jayapal, Spandana C, Srinivas A (2013) Synthesis and biological evaluation of novel 5-benzylidene-[3-(diethyl amino)methyl]-thiazolidine-2,4-dione derivatives having anti-diabetic activity. Int J Pharm Sci Rev Res 22(2): 23–29. https://www.researchgate.net/ publication /265301123

  52. Yang DH, Yang BY, Chen BC, Chen SY (2006) A convenient synthesis of 5-arylidenethiazolidine-2,4-diones on potassium fluoride-aluminium oxide. Org Prep Proced Int 38: 81. https://www.tandfonline.com/doi/abs/10.1080/ 00304940609355982

  53. Tahlan S, Verma PK (2018) Synthesis, SAR and in vitro therapeutic potentials of thiazolidine-2,4-dione. Chem Centr J 12(1): 129. https://bmcchem.biomedcentral.com/articles/https://doi.org/10.1186/s13065-018-0496-0

  54. Zhou Z (2014) Hydroxyl ammonium ionic liquid-catalyzed simple and efficient synthesis of 5-arylidene-2, 4-thiazolidinediones under solvent-free conditions. Green Chem Lett Rev 7 (1): 90–94.‏ https://www.tandfonline.com/doi/full/https://doi.org/10.1080/17518253.2014.895866

  55. Bozic B, Rogan J, Poleti D, Ranic M, Trisovic N, Bozic B, Uscumlic G (2017) Synthesis, characterization and biological activity of 2-(5-arylidene-2,4-dioxotetrahydrothiazole-3-yl) propanoic acid derivatives. Arab J Chem 10: S2637–S2643. https://www.sciencedirect.com/science/article/pii/S1878535213003420

  56. Alt S, Mitchenall LA, Maxwell A, Heide L (2011) Inhibition of DNA topoisomerase IV of staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics. J Antimicrob Chemother 66 (9): 2061–2069. https://pubmed.ncbi.nlm.nih.gov/21693461/

  57. The methodology of the NCI anticancer screening has been described in details: (http://www.dtp.nci.nih.gov), Bethesda, USA

Download references

Author information

Authors and Affiliations

  1. Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt

    Hossameldin A. Aziz, Gamal El-Din A. Abuo-Rahma & Mai E. Shoman

  2. Sohag Cancer Center, Sohag, Egypt

    Hossameldin A. Aziz

  3. Department of Chemistry, Faculty of Science, Sohag University, Sohag, Egypt

    Ahmed M. M. El-Saghier

  4. Department of Biochemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt

    Mohamed Badr

  5. Department of Pharmaceutical Chemistry, Deraya University, New Minia, Minia, Egypt

    Gamal El-Din A. Abuo-Rahma

Authors
  1. Hossameldin A. Aziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed M. M. El-Saghier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Badr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gamal El-Din A. Abuo-Rahma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mai E. Shoman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Gamal El-Din A. Abuo-Rahma or Mai E. Shoman.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 9781 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aziz, H.A., El-Saghier, A.M.M., Badr, M. et al. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities. Mol Divers 26, 1743–1759 (2022). https://doi.org/10.1007/s11030-021-10302-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11030-021-10302-7

Keywords

Search

Navigation